TerSera announces improvement in symptoms of carcinoid syndrome diarrhoea in real-world study of Xermelo (telotristat ethyl)

In prospective observational study (n=684), patients reported significant improvements in symptoms after 3 months of treatment, including mean daily bowel movements (reduced from 6.3 to 2.3; p<0.0001), stool consistency & urgency (by 55% & 73%, respectively; p<0.0001).

SPS commentary:

In 2020, NHS England reviewed evidence and concluded that there was not enough evidence to make the treatment available at that time.

.

Biospace Inc.